PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsCentus Biotherapeutics
Centus Biotherapeutics
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
EquidacentBevacizumab2020-09-24
Renal cell carcinoma
,
Colorectal neoplasms
,
Breast neoplasms
,
Ovarian neoplasms
,
Non-small-cell lung carcinoma
,
Glioblastoma
,
Fallopian tube neoplasms
,
Kidney neoplasms
,
Uterine cervical neoplasms
,
Peritoneal neoplasms
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Bevacizumab
healthy volunteers/patients
,
adenocarcinoma of lung
Bevifimod
clostridium infections
Globulin, immune
neoplasms
Taxane
ovarian neoplasms
,
fallopian tube neoplasms
,
ovarian epithelial carcinoma
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use